Form 4: Ionis Pharmaceuticals CEO Brett P. Monia Acquires Stock Options

Ionis Pharmaceuticals CEO Brett P. Monia was granted stock options to purchase 86,263 shares of common stock at an exercise price of $34.69 on January 2, 2025.

Summary

• On January 2, 2025, Brett P. Monia, CEO of Ionis Pharmaceuticals, was granted non-qualified stock options to purchase 86,263 shares of Ionis Pharmaceuticals common stock.
• The exercise price of the options is $34.69 per share.
• The options were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• The options vest as to 25% of the shares on January 2, 2026, and the remaining shares vest in 36 equal monthly installments over the following three years.
• Following the transaction, Monia directly owns 86,263 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests. The sentiment is moderately positive.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are generally aligned with industry norms to encourage long-term performance.

Stakeholder Impact

• The stock option grant could incentivize the CEO to improve company performance, benefiting shareholders.
• Employees may view the grant positively as it signals confidence in the company's future.

Key Dates